Zhi-Cheng Jing

List of Publications by Year
in descending order

153 papers	12,638 citations	61857 43 h-index	24915 109 g-index
175 all docs	175 docs citations	175 times ranked	9894 citing authors

#	Article	IF	Citations
1	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	1.2	1,919
2	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	13.9	1,168
3	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	13.9	1,120
4	Risk stratification and medical therapy of pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801889.	3.1	614
5	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72.	1.2	596
6	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555.	3.1	582
7	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	5.2	523
8	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology, 2006, 48, 2546-2552.	1.2	498
9	Clinical features of paediatric pulmonary hypertension: a registry study. Lancet, The, 2012, 379, 537-546.	6.3	441
10	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	5.2	307
11	Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension. Circulation, 2013, 127, 624-633.	1.6	291
12	Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.4	266
13	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	5.2	201
14	Registry and Survival Study in Chinese Patients With Idiopathic and Familial Pulmonary Arterial Hypertension. Chest, 2007, 132, 373-379.	0.4	198
15	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313.	3.1	174
16	Vardenafil in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1723-1729.	2.5	162
17	Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era. Chest, 2011, 140, 301-309.	0.4	161
18	Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmunity Reviews, 2018, 17, 1011-1021.	2.5	125

#	Article	IF	Citations
19	Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension. Circulation, 2018, 138, 287-304.	1.6	115
20	Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. European Respiratory Journal, 2014, 44, 963-972.	3.1	110
21	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371.	5.2	97
22	MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. Journal of Translational Medicine, 2011, 9, 159.	1.8	95
23	CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic. Circulation, 2020, 141, e810-e816.	1.6	92
24	Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801609.	3.1	90
25	Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2009, 33, 1354-1360.	3.1	87
26	Adventitial Cell Atlas of wt (Wild Type) and ApoE (Apolipoprotein E)-Deficient Mice Defined by Single-Cell RNA Sequencing. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1055-1071.	1.1	78
27	Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak. European Heart Journal, 2020, 41, 1791-1794.	1.0	78
28	Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart, 2011, 97, 1876-1881.	1.2	70
29	High-altitude pulmonary hypertension. European Respiratory Review, 2009, 18, 13-17.	3.0	67
30	Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2016, 67, 1312-1323.	1.2	67
31	Pulmonary function testing in patients with pulmonary arterial hypertension. Respiratory Medicine, 2009, 103, 1136-1142.	1.3	60
32	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	2.5	59
33	Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2014, 114, 1420-1425.	0.7	54
34	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. Journal of Thrombosis and Thrombolysis, 2020, 50, 267-277.	1.0	54
35	Prolonged QRS Duration. Chest, 2012, 141, 374-380.	0.4	53
36	Oestradiol ameliorates monocrotaline pulmonary hypertensionviaNO, prostacyclin and endothelin-1 pathways. European Respiratory Journal, 2013, 41, 1116-1125.	3.1	53

#	Article	IF	Citations
37	Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric) Tj ETQq1 1 0.784314 rgBT /Overlo	3.8	53
38	The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovascular Research, 2013, 99, 395-403.	1.8	51
39	Lower Socioeconomic Status Is Associated with Worse Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 303-310.	2.5	50
40	Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 925-928.	2.5	49
41	Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice. Journal of Experimental Medicine, 2018, 215, 2175-2195.	4.2	48
42	Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart, 2006, 92, 1131-1137.	1.2	45
43	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44
44	Identifying microRNAs targeting Wnt/Î²-catenin pathway in end-stage idiopathic pulmonary arterial hypertension. Journal of Molecular Medicine, 2016, 94, 875-885.	1.7	43
45	Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis. Hypertension Research, 2016, 39, 302-311.	1.5	42
46	Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. Hypertension Research, 2015, 38, 539-544.	1.5	39
47	Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension. European Respiratory Journal, 2020, 56, 2000522.	3.1	39
48	Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. Heart, 2009, 95, 1531-1536.	1.2	38
49	DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension. Science Advances, 2020, 6, .	4.7	38
50	BMPR2 Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial Hypertension. Circulation: Cardiovascular Genetics, 2012, 5, 511-518.	5.1	35
51	Micro <scp>RNA</scp> â€483 amelioration of experimental pulmonary hypertension. EMBO Molecular Medicine, 2020, 12, e11303.	3.3	35
52	Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients. European Respiratory Journal, 2012, 39, 597-603.	3.1	33
53	Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 433-439.	0.7	32
54	Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study. International Journal of Cardiology, 2014, 177, 61-65.	0.8	32

#	Article	IF	Citations
55	Herpes Simplex Virus Type 2 Infection Is a Risk Factor for Hypertension. Hypertension Research, 2004, 27, 541-544.	1.5	30
56	BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease. International Journal of Cardiology, 2016, 211, 132-136.	0.8	30
57	Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 482-495.	1.1	29
58	Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions. Journal of the American College of Cardiology, 2020, 75, 2463-2477.	1.2	29
59	Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2017, 228, 895-899.	0.8	28
60	Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension. International Journal of COPD, 2017, Volume 12, 3353-3360.	0.9	28
61	Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients. Thrombosis and Haemostasis, 2019, 119, 1403-1408.	1.8	28
62	Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline. Respiratory Research, 2018, 19, 94.	1.4	27
63	Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension. JAMA Cardiology, 2020, 5, 677.	3.0	26
64	Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension. Drug Design, Development and Therapy, 2017, Volume11, 1195-1207.	2.0	25
65	Impact of Pituitaryâ€“Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. Hypertension, 2018, 72, 151-158.	1.3	25
66	Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 704-718.	1.1	25
67	Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Internal and Emergency Medicine, 2019, 14, 521-527.	1.0	25
68	Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. Coronary Artery Disease, 2006, 17, 463-469.	0.3	24
69	Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATPchannel. European Journal of Heart Failure, 2007, 9, 30-36.	2.9	24
70	Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. Thrombosis Journal, 2013, 11, 25.	0.9	24
71	Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension. Respiratory Research, 2014, 15, 119.	1.4	24
72	Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasiaâ€“associated pulmonary hypertension. European Journal of Clinical Investigation, 2013, 43, 1016-1024.	1.7	23

#	Article	IF	Citations
73	Elevated levels of plasma transforming growth factor-Î²1 in idiopathic and heritable pulmonary arterial hypertension. International Journal of Cardiology, 2016, 222, 368-374.	0.8	23
74	Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1386-1395.	3.1	23
75	Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519.	0.3	22
76	Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiographyâ€suspected pulmonary hypertension. Clinical Cardiology, 2017, 40, 95-101.	0.7	21
77	Protective effects of 18Î²-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway. Chemico-Biological Interactions, 2019, 311, 108749.	1.7	21
78	Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2010, 29, 150-156.	0.3	19
79	Clinical features and survival in Takayasuâ€™s arteritis-associated pulmonary hypertension: a nationwide study. European Heart Journal, 2021, 42, 4298-4305.	1.0	19
80	Association between congenital thrombophilia and outcomes in pulmonary embolism patients. Blood Advances, 2020, 4, 5958-5965.	2.5	18
81	Epidemiology of Pulmonary Arterial Hypertension. Current Hypertension Reports, 2013, 15, 638-649.	1.5	17
82	Efficacy of 1, 5, and 20Âmg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. BMC Pulmonary Medicine, 2017, 17, 44.	0.8	17
83	Usefulness of Intravenous Adenosine in Idiopathic Pulmonary Arterial Hypertension as a Screening Agent for Identifying Long-Term Responders to Calcium Channel Blockers. American Journal of Cardiology, 2012, 109, 1801-1806.	0.7	16
84	BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension. Lung, 2014, 192, 625-627.	1.4	16
85	Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2014, 175, 268-273.	0.8	15
86	Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. American Heart Journal, 2015, 170, 96-103.e14.	1.2	15
87	Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients. American Journal of Hypertension, 2019, 32, 1109-1117.	1.0	15
88	Experimental animal models of pulmonary hypertension: Development and challenges. Animal Models and Experimental Medicine, 2022, 5, 207-216.	1.3	15
89	Protective effects of isorhamnetin on pulmonary arterial hypertension: in vivo and in vitro studies. Phytotherapy Research, 2020, 34, 2730-2744.	2.8	14
90	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. Thrombosis Research, 2021, 201, 63-72.	0.8	14

#	Article	IF	Citations
91	The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertension Research, 2009, 32, 911-915.	1.5	13
92	3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis. American Journal of Hypertension, 2019, 32, 426-432.	1.0	13
93	Review Common genetic risk factors of venous thromboembolism in Western and Asian populations. Genetics and Molecular Research, 2016, 15, 15017644.	0.3	12
94	Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison. Heart Asia, 2016, 8, 74-82.	1.1	12
95	Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension. Frontiers in Pharmacology, 2021, 12, 753727.	1.6	12
96	Plasma metabolomics in the perioperative period of defect repair in patients with pulmonary arterial hypertension associated with congenital heart disease. Acta Pharmacologica Sinica, 2022, 43, 1710-1720.	2.8	12
97	Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries. Progress in Respiratory Research, 2012, , 85-93.	0.1	11
98	Optical coherence tomography for hypertensive pulmonary vasculature. International Journal of Cardiology, 2016, 222, 494-498.	0.8	11
99	Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling. Current Pharmaceutical Design, 2016, 22, 4780-4795.	0.9	11
100	Implication of proliferation gene biomarkers in pulmonary hypertension. Animal Models and Experimental Medicine, 2021, 4, 369-380.	1.3	11
101	The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats. International Journal of Molecular Medicine, 2010, 26, 541-7.	1.8	10
102	The limits of oral therapy in pulmonary arterial hypertension management. Therapeutics and Clinical Risk Management, 2015, 11, 1731.	0.9	10
103	Clinical characteristics of pulmonary hypertension in bronchiectasis. Frontiers of Medicine, 2016, 10, 336-344.	1.5	10
104	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. International Journal of Medical Sciences, 2017, 14, 820-828.	1.1	10
105	Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension. Frontiers in Medicine, 2020, 7, 509.	1.2	10
106	Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chinese Medical Journal, 2008, 121, 2497-2503.	0.9	9
107	Effect of intravenous l-carnitine in Chinese patients with chronic heart failure. European Heart Journal Supplements, 2016, 18, A27-A36.	0.0	9
108	IgG4-related disease of pulmonary artery causing pulmonary hypertension. Medicine (United States), 2018, 97, e10698.	0.4	9

#	Article	IF	Citations
109	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180.	0.3	9
110	Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L798-L809.	1.3	8
111	Retrospective Study of Critically Ill COVID-19 Patients With and Without Extracorporeal Membrane Oxygenation Support in Wuhan, China. Frontiers in Medicine, 2021, 8, 659793.	1.2	8
112	Subendocardial Involvement as an Underrecognized Cardiac MRI Phenotype in Myocarditis. Radiology, 2022, 302, 61-69.	3.6	8
113	Percutaneous Pulmonary Angioplasty forÂPatients With Takayasu Arteritis and Pulmonary Hypertension. Journal of the American College of Cardiology, 2022, 79, 1477-1488.	1.2	8
114	Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension. Chest, 2016, 150, 367-373.	0.4	7
115	A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study. International Journal of COPD, 2017, Volume 12, 1741-1751.	0.9	7
116	Prevalence, Genetic Background, andÂClinical Phenotype of CongenitalÂThrombophilia in ChronicÂThromboembolic PulmonaryÂHypertension. JACC Asia, 2022, 2, 247-255.	0.5	7
117	Pediatric Pulmonary Arterial Hypertension. Current Hypertension Reports, 2013, 15, 606-613.	1.5	6
118	Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study. BMC Cardiovascular Disorders, 2016, 16, 201.	0.7	6
119	Shape of the Pulmonary Artery Dopplerâ€Flow Profile Predicts the Hemodynamics of Pulmonary Hypertension Caused by Leftâ€Sided Heart Disease. Clinical Cardiology, 2016, 39, 150-156.	0.7	6
120	Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. Journal of Cardiology, 2018, 71, 494-504.	0.8	6
121	Association Between High FSH, Low Progesterone, and Idiopathic Pulmonary Arterial Hypertension in Women of Reproductive Age. American Journal of Hypertension, 2020, 33, 99-105.	1.0	6
122	New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis. Current Rheumatology Reports, 2020, 22, 25.	2.1	6
123	A Personalized Pulmonary Circulation Model to Non-Invasively Calculate Fractional Flow Reserve for Artery Stenosis Detection. IEEE Transactions on Biomedical Engineering, 2022, 69, 1435-1448.	2.5	6
124	Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism. Cardiovascular Toxicology, 2020, 20, 101-110.	1.1	5
125	Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 628284.	1.1	5
126	Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome. Frontiers in Physiology, 2021, 12, 674909.	1.3	5

#	Article	IF	Citations
127	Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure. Clinical Respiratory Journal, 2019, 13, 148-158.	0.6	4
128	Derivation of an induced pluripotent stem cell line (PUMCHi003-A) from a patient with pulmonary arterial hypertension carrying heterozygous mutation in PTGIS gene. Stem Cell Research, 2020, 46, 101875.	0.3	4
129	Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. Hypertension, 2022, 79, 1348-1360.	1.3	4
130	Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. Chest, 2014, 145, 513A.	0.4	3
131	Wholeâ€exome sequencing improves genetic testing accuracy in pulmonary artery hypertension. Pulmonary Circulation, 2018, 8, 1-9.	0.8	3
132	The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population. International Journal of Cardiology, 2020, 318, 138-143.	0.8	3
133	Complexities of oestradiol pharmacology in pulmonary arterial hypertension. European Respiratory Journal, 2013, 41, 1466-1467.	3.1	2
134	Generation of an induced pluripotent stem cell line (PUMCHi006-A) derived from a patient with pulmonary arterial hypertension carrying heterozygous c.1339 GÂ>ÂA mutation in PTGIS gene. Stem Cell Research, 2020, 49, 102088.	0.3	2
135	Inflammation and cardiovascular diseases. Chronic Diseases and Translational Medicine, 2020, 6, 215-218.	0.9	2
136	Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases. Frontiers in Pharmacology, 2020, 11, 660.	1.6	2
137	How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563.	0.9	2
138	Isoprostane as a promising biomarker in pulmonary arterial hypertension: Preanalytical and analytical viewpoints. Response to letter to the editor. International Journal of Cardiology, 2014, 177, 632-633.	0.8	1
139	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	1.7	1
140	Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1478-1481.	2.5	1
141	The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS). European Heart Journal, 2019, 40, 3881-3885.	1.0	1
142	Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis. BMC Cardiovascular Disorders, 2020, 20, 339.	0.7	1
143	Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 2020, 18, 643-649.	0.6	1
144	Beyond medications: is pulmonary artery denervation the answer for pulmonary arterial hypertension?. AsiaIntervention, 2022, 8, 14-15.	0.1	1

#	Article	IF	Citations
145	Iloprostâ€"different indications and different national experiences in treating pulmonary hypertension. Clinical Research in Cardiology Supplements, 2010, 5, 19-23.	2.0	0
146	High-Altitude Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 199-206.	0.1	0
147	Antioxidant effects of phosphodiesterase-5 inhibitors: reply. Cardiovascular Research, 2013, 100, 170-171.	1.8	0
148	Reply to â€œComment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertensionâ€• International Journal of Cardiology, 2017, 239, 36.	0.8	0
149	Percutaneous coronary intervention equates to placebo procedure in stable angina?. Journal of Thoracic Disease, 2018, 10, E808-E809.	0.6	0
150	When REVEAL meets AMBITION, does it reveal more?. Journal of Heart and Lung Transplantation, 2018, 37, 1397-1398.	0.3	0
151	Bosentan up-front or sequential add-on combination treatment for pulmonary arterial hypertension: long-term effects and prognosis. Academic Journal of Second Military Medical University, 2015, 36, 19.	0.0	0
152	Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 1603.	1.0	0
153	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Novel Biomarker for Prognostic Assessment and Risk Stratification of Acute Pulmonary Embolism. Journal of Clinical Medicine, 2022, 11, 3908.	1.0	0